Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients
Status:
Active, not recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
The overall objective of the study is to assess the potential effects of the long-acting
GLP-1 analogue exenatide in preventing/slowing the progression of cognitive dysfunction and
related biomarkers in dysglycemic/prediabetic patients with mild cognitive impairment (MCI).